secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0000200406-26-000076
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr
------------------------------------------------------------------------

- Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).
- GAAP net earnings $5.24B ($2.14 diluted EPS) vs $11.0B ($4.54) in Q1 2025, down 52% due to prior-year other income.
- Adjusted net earnings $6.61B ($2.70 diluted EPS) vs $6.71B ($2.77), down 1.4% YoY.
- Dividend increased 3.1% to $1.34 per quarter ($5.36 annual), marking 64th consecutive annual increase; payable June 9, 2026 to record May 26.
- Innovative Medicine segment sales $15.4B (+11.2%); MedTech $8.6B (+7.7%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/0000200406-26-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/jnj-20260414.htm
  HTML page:      https://secwatch.observer/filing/0000200406-26-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer